[Federal Register Volume 59, Number 146 (Monday, August 1, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-18680]
[[Page Unknown]]
[Federal Register: August 1, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Conference on Feasibility of Genetic Technology to Close the HIV
Window in Donor Screening; Notice of Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA), Office of the
Commissioner, is sponsoring a public meeting to evaluate the
feasibility and utility of gene amplification techniques to enhance
viral detection in the seronegative ``window'' phase of human
immunodeficiency virus (HIV) infection.
DATES: The public meeting will be held on Monday, September 26, 1994, 7
a.m. to 4 p.m. through Wednesday, September 28, l994, 12 m.
ADDRESSES: The public meeting will be held at the Holiday Inn-Silver
Spring, 8777 Georgia Ave., Silver Spring, MD.
FOR FURTHER INFORMATION CONTACT: Nicholas P. Reuter, Food and Drug
Administration, Office of Health Affairs (HFY-20), 5600 Fishers Lane,
Rockville, MD 20857, 301-443-1382, FAX 301-443-0232. Those persons
interested in attending the meeting should mail their registration to
Nicholas P. Reuter (address above). Registration should include name,
title, organization, address, and telephone number and/or fax number.
There is no charge for this meeting, but advance registration is
required and early registration is encouraged due to seating
limitations. The cutoff date for registration is August 26, l994.
SUPPLEMENTARY INFORMATION: Several novel approaches have been described
for the detection of genetic sequences by amplification. Although these
techniques offer high sensitivity for detection, problems of
nonspecificity, reproducibility and reduced throughput have hampered
their use in routine diagnosis. The program is designed to assess the
current status of technology development and readiness for applications
to donor screening. The procedural and economic aspects of implementing
these techniques will also be discussed.
Dated: July 26, 1994.
Michael R. Taylor,
Deputy Commissioner for Policy.
[FR Doc. 94-18680 Filed 7-29-94; 8:45 am]
BILLING CODE 4160-01-F
